Skip to main content
. 2022 Dec 9;141(13):1560–1573. doi: 10.1182/blood.2022017650

Table 1.

Characteristics of the study cohort

Characteristic Study cohort
Primary EBV infection
EBV reactivation
Immunocompetent
Immunocompromised Transplant recipients
Asymptomatic EBV-seropositive patients (N = 206) Adolescent/adult patients with IM (N = 412) Pediatric patients with IM
(N = 166)
Older patients (N = 28) Patients without PTLD (N = 144) Patients with EBV+PTLD (N = 36)
Female sex, No. (%) 90 (43.6) 181 (43.9) 73 (43.9) 11 (39.2) 61 (42.4) 14 (38.9)
Age, median (min-max), y 22.5 (18-40) 22.1 (15-35) 5.8 (1-14) 71.7 (60-92) 37.8 (14-91) 30.2 (14-74)
EBV status
 EBV RT-qPCR Neg. Pos. Pos. Pos. Pos. Pos.
 VCA IgM Neg. Pos. Pos. Pos. Pos. Pos.
 VCA IgG Pos. Pos. Pos. Pos. Pos. Pos.
 EBNA IgG Pos. Neg. Neg. Pos. Pos. Pos.
Clinical diagnosis None IM IM Unspecific symptoms Unspecific symptoms EBV+PTLD
Transplantation type, No. (%)
 HSCT 15 (10.4) 16 (44.4)
 SOT 129 (89.6) 20 (55.6)
First EBV episode
after transplantation, median (range), d
90 (29-312)
EBV+PTLD diagnosis after transplantation, median (range), d 99 (35-302)
PTLD type, No. (%)
 Early lesions 4 (11.1)
 Monomorphic B-cell PTLD 21 (58.3)
 Polymorphic PTLD 11 (30.6)

EBNA, EBV virus nuclear antigen 1; HSCT, hematopoietic stem cell transplantation; max, maximum; min, minimum; Neg., negative; Pos., positive; RT-qPCR, real-time quantitative polymerase chain reaction; SOT, solid organ transplantation.

As defined by the triad of fever, lymphadenopathy, and tonsillitis.

Unspecific symptoms include fever, weight loss, lymphadenopathy, night sweats, or fatigue.